Capricor reports 76% slower upper-limb decline after deramiocel switch
Capricor said its HOPE-3 extension analysis showed patients who switched from placebo to deramiocel slowed upper-limb decline by 76% over the following year. The result adds a longer-duration clinical readout as the Duchenne program moves toward further regulatory and development milestones.
The story
Capricor Therapeutics presented a 24-month crossover analysis from the open-label extension of its HOPE-3 study at the 2026 World Muscle Society Congress. Patients who began deramiocel after spending a year on placebo slowed upper-limb decline by 76% compared with their own prior year.
The analysis follows the study's placebo-controlled period and extends the observation window to two years, allowing the company to compare each patient's decline before and after switching treatment. It concerns upper-limb function in Duchenne muscular dystrophy, a disease in which maintaining arm function is clinically important as weakness progresses.
The result directly affects Capricor's deramiocel program and its development path in Duchenne muscular dystrophy. The company presented the findings as an open-label extension analysis, so the treatment comparison is based on patients' prior performance rather than a concurrently randomized placebo group.
The next read on the program will depend on how regulators and clinicians assess the durability and design of the evidence, including the crossover structure and the use of patients' own prior year as the comparison. Further company updates and regulatory milestones should clarify how the 24-month findings fit into the program's path forward.
Our read · Mon, Oct 5
CAPR patients switching from placebo to deramiocel slowed upper-limb decline by 76% over the next year.
Why. The 76% within-patient slowing gives Capricor a concrete efficacy signal for deramiocel, but the open-label crossover design makes the durability and regulatory weight of the result the key constraint. Company-specific positioning cannot be tightened from the clinical result alone without a dated forward milestone.
Both cases
What could change this view: A subsequent clinical or regulatory update could show weaker durability or limit the significance of the open-label, within-patient comparison.
Who reported it · 1
Keep reading
More on CAPR
CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for InvestorsLatest on the Wire
AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →Latest on the Wire
Biohaven reports confirmed BHV-1530 responses in two FGFR3 cancersTrump, Xi and Putin pledge more refined fuel after first trilateral summitSky reserve linked to $518 million in illicit activity, investigation findsBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%Continue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseAbout this report
Reported by GlobeNewswire as Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →